A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer

Summary

This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer. A Simon Two-Stage adaptive design will enroll approximately 37 patients into Stage 1, and if criteria are met to move to Stage 2, an additional 47 patients will be enrolled.

Timeline

Start

2022-12-08

Primary completion

2025-05-15

Completion

2025-05-15

Drugs

Indications